Kim Gwang-Ho, Yi Sun Shin
Department of Biomedical Laboratory Science, Soonchunhyang University, Asan, 31538 Republic of Korea.
Lab Anim Res. 2019 Nov 29;35:25. doi: 10.1186/s42826-019-0027-8. eCollection 2019.
In the twenty-first century, high contagious infectious diseases such as SARS (Severe Acute Respiratory Syndrome), MERS (Middle East Respiratory Syndrome), FMD (Foot-and-Mouth Disease) and AI (Avian Influenza) have become very prevalent, causing treat harm to humans and animals in aspect of public health, and economical issues. The critical problem is that newly-reported infectious diseases that humans firstly experience are expected to continue to emerge, and these diseases will be spreading out rapidly. Therefore, rapid and safe supplies of effective vaccines are most pivotal to prevent the rapid prevalent of new infection, but international standards or assessing protocol the safety of urgent vaccines are not established well. In our previous study, since we established a module to assess the brain safety of urgent vaccines, therefore, it is necessary to verify that this established module for assessing brain safety could work effectively in commercially available two vaccines (one killed- and on live-vaccines). We compared the results of Evans blue (EB) assay and qPCR analysis by injection of two kinds of vaccines, PBS and Lipopolysaccharide (LPS) under the condition of the module previously reported. We confirmed that the brain safety test module for urgent vaccine we established is very reproducible. Therefore, it is believed that this vaccine safety testing method can be used to validate brain safety when prompt supply of a newly developed vaccines is needed.
在21世纪，高传染性传染病如SARS（严重急性呼吸综合征）、MERS（中东呼吸综合征）、FMD（口蹄疫）和AI（禽流感）变得非常普遍，在公共卫生和经济方面对人类和动物造成了极大危害。关键问题是，预计人类首次经历的新报告传染病将继续出现，并且这些疾病将迅速传播。因此，快速、安全地供应有效疫苗对于预防新感染的迅速流行最为关键，但紧急疫苗安全性的国际标准或评估方案尚未完善建立。在我们之前的研究中，由于我们建立了一个评估紧急疫苗脑安全性的模块，因此，有必要验证这个已建立的评估脑安全性的模块在两种市售疫苗（一种灭活疫苗和一种活疫苗）中能否有效发挥作用。我们在先前报道的模块条件下，通过注射两种疫苗、PBS和脂多糖（LPS），比较了伊文思蓝（EB）测定和qPCR分析的结果。我们证实，我们建立的紧急疫苗脑安全性测试模块具有很高的可重复性。因此，人们认为，当需要迅速供应新开发的疫苗时，这种疫苗安全性测试方法可用于验证脑安全性。
